PAGES_DCNS 46_5.qxd:DCNS#45
暂无分享,去创建一个
[1] Helena Chmura Kraemer,et al. Clinical trials design lessons from the CATIE study. , 2009, The American journal of psychiatry.
[2] S. Leucht,et al. Comparative remission rates of schizophrenic patients using various remission criteria , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[3] S. Kapur,et al. Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders , 2008, Schizophrenia Research.
[4] L. Hranov,et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial , 2008, The Lancet.
[5] J. Lieberman,et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. , 2007, The American journal of psychiatry.
[6] Yue-Cune Chang,et al. Optimizing Early Prediction for Antipsychotic Response in Schizophrenia , 2006, Journal of clinical psychopharmacology.
[7] Peter B. Jones,et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.
[8] J. Lieberman,et al. Olanzapine and haloperidol in first episode psychosis: Two-year data , 2006, Schizophrenia Research.
[9] J. Lieberman,et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. , 2006, The American journal of psychiatry.
[10] Peter B. Jones,et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. , 2005, Schizophrenia bulletin.
[11] J. Kane,et al. Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended , 2005, Biological Psychiatry.
[12] Philip D. Harvey,et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. , 2005, The American journal of psychiatry.
[13] D. Weinberger,et al. Remission in schizophrenia: proposed criteria and rationale for consensus. , 2005, The American journal of psychiatry.
[14] Robert M Bilder,et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. , 2004, The American journal of psychiatry.
[15] Julie Kreyenbuhl,et al. Practice guideline for the treatment of patients with schizophrenia , 1997 .
[16] J. Lieberman,et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. , 2003, The American journal of psychiatry.
[17] C. Correll,et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. , 2003, The American journal of psychiatry.
[18] S. Kapur,et al. Delayed onset hypothesis of antipsychotic action — a hypothesis tested and rejected , 2003, Schizophrenia Research.
[19] R. Liberman,et al. Teaching persons with severe mental disabilities to be their own case managers. , 2002, Psychiatric services.
[20] N Freemantle,et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis , 2000, BMJ : British Medical Journal.
[21] A Labelle,et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. , 2000, Archives of general psychiatry.
[22] J. Lieberman,et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. , 1999, Archives of general psychiatry.
[23] A. Breier,et al. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia∗ ∗ See accompanying Editorial, in this issue. , 1999, Biological Psychiatry.
[24] R. Conley,et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. , 1998, The American journal of psychiatry.
[25] N. Schooler. 199. Comparing new anti-psychotic medications: What do the data say? , 1998, Biological Psychiatry.
[26] C. Eap,et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. , 1998, The American journal of psychiatry.
[27] A. Baldacchino,et al. THE USE OF OLANZAPINE IN NON-COMPLIANT OR TREATMENT-RESISTANT CLOZAPINE POPULATIONS IN HOSPITAL , 1998 .
[28] M. Tohen,et al. Olanzapine vs. placebo in rapid-cycling bipolar disorder , 1998, Schizophrenia Research.
[29] Michael F. Green,et al. 605 Risperidone's effects on verbal working memory , 1997, Schizophrenia Research.
[30] M. Cuesta,et al. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia. , 1997, The Journal of clinical psychiatry.
[31] G. Tollefson,et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. , 1997 .
[32] J. Peuskens,et al. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia , 1997, Acta psychiatrica Scandinavica.
[33] R. Rosenheck,et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1997, The New England journal of medicine.
[34] R. Tamura,et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. , 1997 .
[35] L. Arvanitis,et al. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo , 1997, Biological Psychiatry.
[36] C. Tamminga,et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group. , 1997, The American journal of psychiatry.
[37] J. Lieberman,et al. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. , 1997, Archives of general psychiatry.
[38] R. Tamura,et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. , 1997, The American journal of psychiatry.
[39] Kane Jm. Commentary on the clozapine conflict. , 1996 .
[40] A. Malhotra,et al. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. , 1996, The American journal of psychiatry.
[41] Michael F. Green,et al. What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.
[42] R. Bilder,et al. The effects of clozapine and haldol on memory functioning in treatment refractory schizophrenics , 1996, Schizophrenia Research.
[43] Charles M Beasley,et al. Olanzapine versus Placebo and Haloperidol , 1996, Neuropsychopharmacology.
[44] M. J. Arranz,et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene , 1995, The Lancet.
[45] H. Meltzer,et al. Clozapine: is another view valid? , 1995, The American journal of psychiatry.
[46] R. Conley,et al. Patient response and resource management: another view of clozapine treatment of schizophrenia. , 1995, The American journal of psychiatry.
[47] D. Jeste,et al. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. , 1995, Archives of general psychiatry.
[48] R. Baldessarini,et al. Neuroleptic withdrawal in schizophrenic patients. , 1995, Archives of general psychiatry.
[49] C. Wurthmann,et al. Randomized, Double‐Blind, Controlled Trial of Risperidone Versus Clozapine in Patients With Chronic Schizophrenia , 1995, Journal of clinical psychopharmacology.
[50] M. Tohen,et al. One hundred years of schizophrenia: a meta-analysis of the outcome literature. , 1994 .
[51] S. Marder,et al. Risperidone in the treatment of schizophrenia. , 1994, The American journal of psychiatry.
[52] John M. Davis,et al. Depot Antipsychotic Drugs , 1994, Drugs.
[53] Green Ai,et al. Decreased substance use in chronically psychotic patients treated with clozapine. , 1994 .
[54] L. Friedman,et al. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine , 1993, Biological Psychiatry.
[55] W. Gaebel,et al. Intermittent versus maintenance neuroleptic long-term treatment in Schizophrenia—2-year results of a German multicenter study , 1993 .
[56] S Pollack,et al. Does clozapine cause tardive dyskinesia? , 1993, The Journal of clinical psychiatry.
[57] E. Češková,et al. Double-blind Comparison of Risperidone and Haloperidol in Schizophrenic and Schizoaffective Psychoses , 1993, Pharmacopsychiatry.
[58] Philip D. Harvey,et al. Cognitive deficits in schizophrenia. , 1993, The Psychiatric clinics of North America.
[59] P. Janicak. Principles and Practice of Psychopharmacotherapy , 1993 .
[60] J. Wilkins,et al. Unrecognized cocaine use among schizophrenic patients. , 1993, The American journal of psychiatry.
[61] S. Marder,et al. A one-year comparison of four dosages of haloperidol decanoate , 1993, Schizophrenia Research.
[62] H. Hermesh,et al. Poor neuroleptic response in acutely exacerbated schizophrenic patients , 1993, Acta psychiatrica Scandinavica.
[63] G. Remington,et al. Acutely psychotic patients receiving high-dose haloperidol therapy. , 1993, Journal of clinical psychopharmacology.
[64] A Labelle,et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. , 1993, Journal of clinical psychopharmacology.
[65] J. Kane,et al. Depot neuroleptic therapy: an underutilized treatment option. , 1992, The Journal of clinical psychiatry.
[66] A. Mallya,et al. Restraint, seclusion, and clozapine. , 1992, The Journal of clinical psychiatry.
[67] P. Czobor,et al. Haloperidol blood levels and clinical effects. , 1992, Archives of general psychiatry.
[68] R E Litman,et al. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. , 1992, Archives of general psychiatry.
[69] J. Peuskens,et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study , 1992, Acta psychiatrica Scandinavica.
[70] M. Herz,et al. Intermittent vs maintenance medication in schizophrenia. Two-year results. , 1991, Archives of general psychiatry.
[71] A. Rifkin,et al. Dosage of haloperidol for schizophrenia. , 1991, Archives of general psychiatry.
[72] D S Rae,et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. , 1990, JAMA.
[73] S. Hirsch,et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years. , 1990 .
[74] R. Buchanan,et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. , 1990, The American journal of psychiatry.
[75] G. Simpson,et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. , 1990, Archives of general psychiatry.
[76] S. Marder,et al. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. , 1990, Archives of general psychiatry.
[77] N. Andreasen. The Scale for the Assessment of Negative Symptoms (SANS): Conceptual and Theoretical Foundations , 1989, British Journal of Psychiatry.
[78] S. Hirsch,et al. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year. , 1989, BMJ.
[79] J. McEvoy,et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. , 1988, Archives of general psychiatry.
[80] G Honigfeld,et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.
[81] D. A. Johnson,et al. Double-Blind Comparison of Half-Dose and Standard-Dose Flupenthixol Decanoate in the Maintenance Treatment of Stabilised Out-Patients with Schizophrenia , 1987, British Journal of Psychiatry.
[82] S. Marder,et al. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. , 1987, Archives of general psychiatry.
[83] J. Kane,et al. Depot neuroleptics: a comparative review of standard, intermediate, and low-dose regimens. , 1986, Journal of Clinical Psychiatry.
[84] J. Kane. Compliance Issues in Outpatient Treatment , 1985, Journal of clinical psychopharmacology.
[85] S. Marder,et al. Costs and benefits of two doses of fluphenazine. , 1984, Archives of general psychiatry.
[86] A. Rifkin,et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. , 1983, Archives of general psychiatry.
[87] J. Kane,et al. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979 , 1982, Archives of general psychiatry.
[88] G. Hogarty,et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. , 1979, Archives of general psychiatry.
[89] J. Curran. PROGRESS IN PSYCHIATRIC DRUG TREATMENT , 1977 .
[90] J. Davis,et al. Overview: maintenance therapy in psychiatry: I. Schizophrenia. , 1975, The American journal of psychiatry.
[91] F. Quitkin,et al. Very High Dosage vs Standard Dosage Fluphenazine in Schizophrenia: Frederic Quitkin, MD; Arthur Rifkin, MD; Donald F. Klein, MD , 1975 .
[92] D. Klein. Diagnosis and Drug Treatment of Psychiatric Disorders , 1969, British Journal of Psychiatry.
[93] Jonathan O. Cole,et al. High Dose Chlorpromazine Therapy in Chronic Schizophrenia: Report of National Institute of Mental Health—Psychopharmacology Research Branch Collaborative Study Group , 1968 .
[94] Daniel M. Hartung,et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. , 2010, Archives of general psychiatry.
[95] D. Casey. Clozapine: neuroleptic-induced EPS and tardive dyskinesia , 2004, Psychopharmacology.
[96] J. Gerlach,et al. High dosage haloperidol therapy in chronic schizophrenic patients: A double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin , 2004, Psychopharmacology.
[97] J. Kane,et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. , 2003, The Journal of clinical psychiatry.
[98] W. Honer,et al. An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. , 1998, Pharmacopsychiatry.
[99] R. Fireworker,et al. Clozapine reduces rehospitalization among schizophrenia patients. , 1998, Psychopharmacology bulletin.
[100] M. Tohen,et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. , 1997, Archives of general psychiatry.
[101] J. Kane,et al. Drug therapy : schizophrenia , 1996 .
[102] W A Hargreaves,et al. Clozapine eligibility among state hospital patients. , 1996, Schizophrenia bulletin.
[103] Nancy H. Covell,et al. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. , 1996, Psychopharmacology bulletin.
[104] H. Meltzer,et al. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. , 1995, The American journal of psychiatry.
[105] M. Olfson,et al. The Cost of Relapse in Schizophrenia , 2017, PharmacoEconomics.
[106] H. Meltzer,et al. Substance abuse among patients with treatment-resistant schizophrenia: characteristics and implications for clozapine therapy. , 1994, The American journal of psychiatry.
[107] R. Buchanan,et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. , 1994, The American journal of psychiatry.
[108] P. Weiden,et al. Treatment of neuroleptic-resistant schizophrenic relapse. , 1993, Psychopharmacology bulletin.
[109] B. Cornblatt,et al. The New York High-Risk Project: anhedonia, attentional deviance, and psychopathology. , 1993, Schizophrenia bulletin.
[110] F. Müller-Spahn. RISPERIDONE IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS: AN INTERNATIONAL DOUBLE‐BLIND PARALLEL‐GROUP STUDY VERSUS HALOPERIDOL. , 1992, Clinical neuropharmacology.
[111] B. Diamond,et al. Risperidone: clinical safety and efficacy in schizophrenia. , 1992, Psychopharmacology bulletin.
[112] Werner Kissling. Guidelines for Neuroleptic Relapse Prevention in Schizophrenia , 1991, Springer Berlin Heidelberg.
[113] R. Wyatt,et al. When symptoms persist: choosing among alternative somatic treatments for schizophrenia. , 1991, Schizophrenia bulletin.
[114] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.
[115] M. Borenstein,et al. Compliance in the long-term treatment of schizophrenia. , 1985, Psychopharmacology bulletin.
[116] Barbara A. Cornblatt,et al. The New York High-Risk Project. , 1984 .